Malady Kyle 4

What Happened

• Kyle Malady, Executive Vice President and Group CEO — VZ Business at Verizon Communications (VZ), received an award of 120.141 phantom shares on 2026-03-26. The award is recorded at $14.47 per share for a notional value of approximately $1,738. This was an award/acquisition (transaction code A), not an open‑market purchase or sale.

Key Details

• Transaction date and price: 2026-03-26 at $14.47 per phantom share.
• Transaction value: ~ $1,738 (derivative, cash‑settled phantom stock).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnotes: F1 — each phantom share is economically equivalent to a portion of one share of Verizon common stock and is settled in cash; payout occurs per the reporting person’s elections under the deferred compensation plan. F2 — the amount includes phantom stock acquired through dividend reinvestment.
• Filing timeliness: Form 4 was filed 2026-03-30 for a 2026-03-26 transaction; this meets the typical two-business-day filing window and is not marked late.
• Exhibit: Exhibit 24 (Power of Attorney) included.

Context

• This transaction is a derivative award (phantom stock) tied to Verizon common stock but settled in cash under a deferred compensation plan. Such awards are routine executive compensation and do not represent an open‑market purchase or sale of actual shares. For retail investors, purchases or open‑market buys often carry clearer signals than routine deferred‑compensation awards.